Latest Insider Transactions at Organogenesis Holdings Inc. (ORGO)
This section provides a real-time view of insider transactions for Organogenesis Holdings Inc. (ORGO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Organogenesis Holdings Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Organogenesis Holdings Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 16
2022
|
Michael W Katz > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
10,000
+4.73%
|
$60,000
$6.04 P/Share
|
|
May 16
2022
|
Gary S. Gillheeney President and CEO |
SELL
Open market or private sale
|
Direct |
80,369
-16.79%
|
$401,845
$5.92 P/Share
|
|
May 16
2022
|
Gary S. Gillheeney President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
80,369
+14.38%
|
$0
$0.99 P/Share
|
|
May 13
2022
|
Gary S. Gillheeney President and CEO |
SELL
Open market or private sale
|
Direct |
136,390
-13.08%
|
$818,340
$6.12 P/Share
|
|
May 13
2022
|
Gary S. Gillheeney President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
136,390
+10.99%
|
$0
$0.99 P/Share
|
|
May 03
2022
|
Michele Ilene Korfin Director |
BUY
Grant, award, or other acquisition
|
Direct |
23,913
+50.0%
|
-
|
|
May 03
2022
|
Gilberto Quintero Director |
BUY
Grant, award, or other acquisition
|
Direct |
23,913
+50.0%
|
-
|
|
Apr 01
2022
|
Patrick Bilbo Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,497
-1.34%
|
$17,479
$7.89 P/Share
|
|
Apr 01
2022
|
Lori Freedman Chief Admin. and Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,984
-3.99%
|
$20,888
$7.89 P/Share
|
|
Apr 01
2022
|
Antonio S. Montecalvo Vice President, Health Policy |
SELL
Payment of exercise price or tax liability
|
Direct |
2,738
-6.18%
|
$19,166
$7.89 P/Share
|
|
Apr 01
2022
|
Gary S. Gillheeney President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
9,789
-2.4%
|
$68,523
$7.89 P/Share
|
|
Apr 01
2022
|
Brian Grow Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,977
-2.22%
|
$13,839
$7.89 P/Share
|
|
Mar 10
2022
|
Antonio S. Montecalvo Vice President, Health Policy |
SELL
Open market or private sale
|
Direct |
97,436
-68.75%
|
$779,488
$8.39 P/Share
|
|
Mar 10
2022
|
Antonio S. Montecalvo Vice President, Health Policy |
BUY
Exercise of conversion of derivative security
|
Direct |
68,504
+20.76%
|
$205,512
$3.46 P/Share
|
|
Mar 09
2022
|
Antonio S. Montecalvo Vice President, Health Policy |
SELL
Open market or private sale
|
Direct |
10,000
-12.02%
|
$80,000
$8.52 P/Share
|
|
Feb 16
2022
|
Gary S. Gillheeney President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,085
-0.99%
|
$28,595
$7.78 P/Share
|
|
Feb 16
2022
|
David Francisco Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
953
-1.74%
|
$6,671
$7.78 P/Share
|
|
Feb 16
2022
|
Lori Freedman Chief Admin. and Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
765
-1.01%
|
$5,355
$7.78 P/Share
|
|
Feb 16
2022
|
Patrick Bilbo Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
937
-0.5%
|
$6,559
$7.78 P/Share
|
|
Feb 16
2022
|
Brian Grow Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
799
-0.89%
|
$5,593
$7.78 P/Share
|
|
Feb 16
2022
|
Antonio S. Montecalvo Vice President, Health Policy |
SELL
Payment of exercise price or tax liability
|
Direct |
718
-0.86%
|
$5,026
$7.78 P/Share
|
|
Feb 15
2022
|
Gary S. Gillheeney President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
280,199
+40.47%
|
-
|
|
Feb 15
2022
|
David Francisco Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,876
-3.31%
|
$15,008
$8.03 P/Share
|
|
Feb 15
2022
|
David Francisco Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,348
+41.57%
|
-
|
|
Feb 15
2022
|
Lori Freedman Chief Admin. and Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
41,843
+35.63%
|
-
|
|
Feb 15
2022
|
Patrick Bilbo Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
52,926
+22.1%
|
-
|
|
Feb 15
2022
|
Brian Grow Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
45,143
+33.47%
|
-
|
|
Feb 15
2022
|
Antonio S. Montecalvo Vice President, Health Policy |
BUY
Grant, award, or other acquisition
|
Direct |
14,383
+14.63%
|
-
|
|
Feb 15
2022
|
Arthur S Leibowitz Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,547
+23.24%
|
-
|
|
Feb 15
2022
|
Jon L Giacomin Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,547
+44.27%
|
-
|
|
Feb 15
2022
|
Prathyusha Duraibabu Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,547
+39.19%
|
-
|
|
Feb 15
2022
|
Michael Joseph Driscoll Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,547
+50.0%
|
-
|
|
Dec 28
2021
|
Albert Erani Family Trust Dated 12/29/2012 > 10% Shareholder |
BUY
Bona fide gift
|
Direct |
12,053,457
+9.17%
|
-
|
|
Dec 28
2021
|
Albert Erani Family Trust Dated 12/29/2012 > 10% Shareholder |
SELL
Bona fide gift
|
Direct |
7,392,328
-11.06%
|
-
|
|
Dec 28
2021
|
Albert Erani Family Trust Dated 12/29/2012 > 10% Shareholder |
SELL
Bona fide gift
|
Indirect |
4,661,129
-7.27%
|
-
|
|
Dec 28
2021
|
Red Holdings, LLC > 10% Shareholder |
BUY
Bona fide gift
|
Direct |
12,053,457
+9.17%
|
-
|
|
Dec 28
2021
|
Red Holdings, LLC > 10% Shareholder |
SELL
Bona fide gift
|
Direct |
7,392,328
-11.06%
|
-
|
|
Dec 28
2021
|
Red Holdings, LLC > 10% Shareholder |
SELL
Bona fide gift
|
Indirect |
4,661,129
-7.27%
|
-
|
|
Dec 15
2021
|
Dennis Erani 2012 Issue Trust Dated 12/20/12 > 10% Shareholder |
BUY
Bona fide gift
|
Direct |
5,417,900
+8.35%
|
-
|
|
Dec 15
2021
|
Dennis Erani 2012 Issue Trust Dated 12/20/12 > 10% Shareholder |
SELL
Bona fide gift
|
Indirect |
5,417,900
-8.35%
|
-
|
|
Dec 15
2021
|
Dennis Erani > 10% Shareholder |
BUY
Bona fide gift
|
Direct |
5,417,900
+8.35%
|
-
|
|
Dec 15
2021
|
Dennis Erani > 10% Shareholder |
SELL
Bona fide gift
|
Indirect |
5,417,900
-8.35%
|
-
|
|
Dec 13
2021
|
Michael W Katz > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
500
+0.82%
|
$4,500
$9.65 P/Share
|
|
Dec 03
2021
|
Michael W Katz > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
800
+1.32%
|
$7,200
$9.35 P/Share
|
|
Dec 02
2021
|
Michael W Katz > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,800
+1.51%
|
$16,200
$9.65 P/Share
|
|
Nov 29
2021
|
Michael W Katz > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,000
+1.72%
|
$9,000
$9.75 P/Share
|
|
Nov 26
2021
|
Michael W Katz > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
2,000
+1.76%
|
$18,000
$9.79 P/Share
|
|
Nov 19
2021
|
Prathyusha Duraibabu Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,340
+50.0%
|
-
|
|
Nov 18
2021
|
Glenn H Nussdorf Director |
BUY
Open market or private purchase
|
Direct |
25,000
+0.04%
|
$225,000
$9.93 P/Share
|
|
Nov 18
2021
|
Gn 2016 Organo 10 Year Grat U/A/D September 30, 2016 > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
25,000
+0.04%
|
$225,000
$9.93 P/Share
|